维生素D影响双磷酸盐类药物治疗抗骨质疏松效果的研究进展-《医学研究与战创伤救治》（原医学研究生学报）

参考文献/References:

[1]王桦, 赵晟珣, 曾尔亢, 等. 中国人口老龄化社会发展与应对策略, 2014, 31(2): 75-77.
[2]原发性骨质疏松症诊疗指南(2017)[J].中华骨质疏松和骨矿盐疾病杂志,2017,10(5):413-443.
[3]张智海, 张智若, 刘忠厚, 等. 中国大陆地区以-2.0SD为诊断标准的骨质疏松症发病率回顾性研究[J].中国骨质疏松杂志,2016,22(1):1-8.
[4]Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial[J]. J Clin Endocrinol Metab, 2001,86(3):1212-1221.
[5]Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial[J]. JAMA, 2010,303(18):1815-1822.
[6]张智海, 刘忠厚, 李娜, 等. 中国人骨质疏松症诊断标准专家共识(第三稿·2014版)[J].中国骨质疏松杂志,2014,20(9):1007-1010
[7]王耿杰，倪连红，马良赟. 骨质疏松性骨折预测方法的研究进展[J].东南国防医药,2017,19(5):513-516.
[8]原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
[9]徐若男，王丁丁，朱小蔚. 预防和治疗骨质疏松症的常用药物[J].东南国防医药,2011,13(6):540-541.
[10]Nancollas G H, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.[J]. Bone, 2006, 38(5):617-627.
[11]Russell RG, Watts NB, Ebetino FH, et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy[J]. Osteoporos Int, 2008,19(6):733-759.
[12]孔瑞娜, 高洁, 张菊, 等. 唑来膦酸对女性骨质疏松症的疗效及其对骨标志物的影响[J].中国骨质疏松杂志,2017,23(4):496-501.
[13]Cashman KD, Dowling KG, krabáková Z, et al. Vitamin D deficiency in Europe: pandemic?[J] Am J Clin Nutr, 2016,103(4):1033-1044.
[14]廖祥鹏, 张增利, 张红红, 等. 维生素D与成年人骨骼健康应用指南(2014年标准版)[J].中国骨质疏松杂志,2014,20(9):1011-1030
[15]黄启钊, 戚华兵, 杜晓兰, 等. 维生素D信号通路在骨骼稳态维持中的作用[J].中华骨质疏松和骨矿盐疾病杂志,2015,8(2):156-163.
[16]Heckman GA, Papaioannou A, Sebaldt RJ, et al. Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates[J]. BMC Musculoskelet Disord, 2002,3:6.
[17]Cairoli E, Eller-Vainicher C, Ulivieri FM, et al. Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis[J]. Osteoporos Int, 2014,25(4):1401-1410
[18]Mastaglia SR, Pellegrini GG, Mandalunis PM, et al. Vitamin D insufficiency reduces the protective effect of bisphosphonate on ovariectomy-induced bone loss in rats[J]. Bone, 2006,39(4):837-844.
[19]Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis[J]. Osteoporos Int, 2009,20(2):239-244.
[20]Ishijima M, Yamanaka M, Sakamoto Y. Vitamin D insufficiency impairs the effect of alendronate for the treatment of osteoporosis in postmenopausal women[J]. J Bone Miner, 2005,1.
[21]Mosali P, Bernard L, Wajed J, et al. Vitamin D status and parathyroid hormone concentrations influence the skeletal response to zoledronate and denosumab[J]. Calcif Tissue Int, 2014,94(5):553-559.
[22]Bonnick S, Broy S, Kaiser F, et al. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density[J]. Curr Med Res Opin, 2007,23(6):1341-1349.
[23]Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study[J]. J Bone Miner Res, 2006,21(10):1565-1570
[24]Antoniucci DM, Vittinghoff E, Palermo L, et al. Vitamin D insufficiency does not affect response of bone mineral density to alendronate[J]. Osteoporos Int, 2009,20(7):1259-1266.
[25]Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women[J]. Calcif Tissue Int, 2009,85(5):398-404.
[26]Carmel AS, Shieh A, Bang H, et al. The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml[J].Osteoporos Int,2012,23(10):2479-2487.
[27]李毅中, 郭良瑞, 蔡思清, 等. 双膦酸盐治疗骨质疏松症时每日补充维生素d800～1200iu是否足够？[J] 中国骨质疏松杂志,2016,22(3):257-260
[28]Atkins GJ, Anderson PH, Findlay DM, et al. Metabolism of vitamin D3 in human osteoblasts: Evidence for autocrine and paracrine activities of 1α,25-dihydroxyvitamin D3[J].Bone,2007,40(6):1517-1528.
[29]van Driel M, Koedam M, Buurman CJ, et al. Evidence for auto/paracrine actions of vitamin D in bone: 1alpha-hydroxylase expression and activity in human bone cells[J]. FASEB J, 2006,20(13):2417-2419.
[30]Kogawa M, Findlay DM, Anderson PH, et al. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption[J]. Endocrinology, 2010,151(10):4613-4625.
[31]Iba K, Sonoda T, Takada J, et al. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment[J]. J Bone Miner Metab, 2017,35(2):171-176.
[32]Walsh MC, Choi Y. Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond[J]. Front Immunol, 2014,5:511.
[33]李子怡, 李玉坤. OPG/RANK/RANKL信号通路在骨质疏松症中的研究进展和应用[J].中华老年骨科与康复电子杂志,2017,3(2):124-128.
[34]仲蕾蕾, 杨冰, 黄晓斌, 等. opg／rankl／rank系统在成骨细胞和破骨细胞相互调节中的作用[J].中国骨质疏松杂志,2011,17(11):1010-1013.
[35]Deane A, Constancio L, Fogelman I, et al. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis[J]. BMC Musculoskelet Disord, 2007,8:3.
[36]Kharroubi A, Saba E, Smoom R, et al. Serum 25-hydroxyvitamin D and bone turnover markers in Palestinian postmenopausal osteoporosis and normal women[J]. Arch Osteoporos, 2017,12(1):13.
[37]Arantes HP, Kulak CA, Fernandes CE, et al. Correlation between 25-hydroxyvitamin D levels and latitude in Brazilian postmenopausal women: from the Arzoxifene Generations Trial[J]. Osteoporos Int, 2013,24(10):2707-2712.
[38]李梅, 章振林, 李艳, 等. 健康汉族男女性血清骨转换生化指标p1np和β-ctx浓度范围再分析[J].中华骨质疏松和骨矿盐疾病杂志,2016,9(1):7-13.
[39]Holick MF. Optimal vitamin D status for the prevention and treatment of osteoporosis[J]. Drugs Aging, 2007,24(12):1017-1029.
[40]Lu C, Yang J, Yu W, et al. Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis[J]. PLoS One, 2015, 10(7):e0132036.

相似文献/References:

[1]马丽萍,王剑火,姜绪防,等.碳酸钙维生素D_3及鲑鱼降钙素联合脉冲电磁场治疗老年女性骨质疏松症的临床观察[J].医学研究与战创伤救治(原医学研究生学报),2013,15(02):154.
　.Health-center of Fuzhou Tenth Cadres Sanatorium of Fujian Povincial Military District,Fuzhou,Fujian 000,et al.MA Li-ping 1,WANG Jian-huo 2,JIANG Xu-fang 3[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(03):154.
[2]邓云,丁惠,居颂光,等.复发性自然流产的病因及治疗现状[J].医学研究与战创伤救治(原医学研究生学报),2013,15(02):167.
[3]马晓华,杨俊,吴心颖,等.桡骨定量骨超声检测的临床应用价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(03):290.[doi:10.3969/j.issn.1672-271X.2013.03.027]
[4]李向阳,樊荣,丁友宏,等.十二指肠营养管外套胃肠引流管在胃瘫患者中的应用[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):461.[doi:10.3969/j.issn.1672-271X.2013.05.010]
　LI Xiang-yang,FAN Rong,DING You-hong,et al.Application of duodenal nutrition tube jacket gastrointestinal drainage tube in treatment for gastric paralysis after esophagectomy[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(03):461.[doi:10.3969/j.issn.1672-271X.2013.05.010]
[5]张智斌,阙镇如,冉骞,等.低温等离子刀与传统手术治疗会厌囊肿的比较分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):515.[doi:10.3969/j.issn.1672-271X.2013.05.028]
[6]李鹏,孙星慧,蒋晓明.睾丸胚胎性横纹肌肉瘤1例并文献复习[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):517.[doi:10.3969/j.issn.1672-271X.2013.05.029]
[7]王峻峰,沈旭峰,袁挺,等.驻某地军人急腹症的临床分析[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):68.
[8]徐健,赵秋良,张维维.成功救治危重症哮喘致呼吸心搏骤停1例[J].医学研究与战创伤救治(原医学研究生学报),2013,15(01):63.
[9]杨林东,周秋明,李娜.原发性输卵管移行细胞癌1例[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):128.
[10]梁菁菁,蒋戚,邹大进.羟氯喹治疗2型糖尿病[J].医学研究与战创伤救治(原医学研究生学报),2012,14(03):267.
[11]徐若男,王丁丁,朱小蔚.预防和治疗骨质疏松症的常用药物[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):540.

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

文章信息/Info

参考文献/References:

相似文献/References:

备注/Memo

常用功能

导航/Navigate

工具/Tools

统计/Statistics